Crinetics Pharmaceuticals, Inc. (CRNX)
$84.95+0.00%Close
BUYBULL · day 39
Key stats
- Market cap
- $9.0B
- Beta
- 0.13
- P/E (TTM)
- -16.82
- 1W
- +0.13%
- 1M
- +1.30%
- vs SPY 1W
- -0.29%
- vs SPY 1M
- -0.76%
Industry peers
FMP comparable companies · ranked by market cap
- KYMRSELLKymera Therapeutics, Inc.$9.0BBEARQ 25$109.30-0.28%
- PRAXSELLPraxis Precision Medicines, Inc.$7.3BCRISISQ 11$263.55-3.26%
- IMVTSELLImmunovant, Inc.$6.2BCRISISQ 25$30.26-3.25%
- AKROAkero Therapeutics, Inc.$4.5B$54.65
- XENESELLXenon Pharmaceuticals Inc.$3.5BCRISISQ 22$36.16-1.73%
- ACADSELLAcadia Pharmaceuticals Inc.$3.4BCRISISQ 18$19.58-1.87%
- VKTXSELLViking Therapeutics, Inc.$3.2BCRISISQ 22$27.73-0.60%
- DYNSELLDyne Therapeutics, Inc.$3.1BRECOVERYQ 3$16.37-4.09%
- SLNOSoleno Therapeutics, Inc.$2.8B$53.01
- NAMSSELLNewAmsterdam Pharma Company N.V.$2.5BCRISISQ 25$21.26-1.53%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on CRNX?
- LOPJLB’s latest quantitative signal on Crinetics Pharmaceuticals, Inc. (CRNX) is BUY in a BULL regime. Signals are updated daily.
- What market regime is CRNX in?
- Crinetics Pharmaceuticals, Inc. (CRNX) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Crinetics Pharmaceuticals, Inc. (CRNX) do?
- Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has conclude…